Invesco Ltd. Has $161,000 Holdings in Astria Therapeutics, Inc. (NASDAQ:ATXS)

Invesco Ltd. lowered its holdings in Astria Therapeutics, Inc. (NASDAQ:ATXS - Free Report) by 94.3% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 17,992 shares of the biotechnology company's stock after selling 296,814 shares during the period. Invesco Ltd.'s holdings in Astria Therapeutics were worth $161,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also modified their holdings of ATXS. Barclays PLC grew its stake in Astria Therapeutics by 70.5% during the 3rd quarter. Barclays PLC now owns 92,651 shares of the biotechnology company's stock valued at $1,020,000 after acquiring an additional 38,321 shares in the last quarter. Teacher Retirement System of Texas purchased a new stake in Astria Therapeutics in the 4th quarter worth approximately $91,000. KLP Kapitalforvaltning AS purchased a new position in shares of Astria Therapeutics during the 4th quarter valued at $41,000. American Century Companies Inc. increased its stake in shares of Astria Therapeutics by 9.9% in the fourth quarter. American Century Companies Inc. now owns 42,693 shares of the biotechnology company's stock worth $382,000 after acquiring an additional 3,839 shares during the last quarter. Finally, JPMorgan Chase & Co. raised its holdings in shares of Astria Therapeutics by 101.7% during the third quarter. JPMorgan Chase & Co. now owns 39,144 shares of the biotechnology company's stock worth $431,000 after acquiring an additional 19,735 shares in the last quarter. Hedge funds and other institutional investors own 98.98% of the company's stock.

Analyst Upgrades and Downgrades

ATXS has been the topic of several research reports. Wedbush reaffirmed an "outperform" rating and issued a $28.00 target price (up from $27.00) on shares of Astria Therapeutics in a research report on Wednesday, March 12th. Citizens Jmp upgraded shares of Astria Therapeutics to a "strong-buy" rating in a research note on Friday, January 31st. HC Wainwright reaffirmed a "buy" rating and issued a $16.00 price objective on shares of Astria Therapeutics in a research note on Tuesday, March 11th. Cantor Fitzgerald raised shares of Astria Therapeutics to a "strong-buy" rating in a research report on Tuesday, April 29th. Finally, JMP Securities initiated coverage on Astria Therapeutics in a research report on Friday, January 31st. They issued an "outperform" rating and a $26.00 price target for the company. Five equities research analysts have rated the stock with a buy rating and three have issued a strong buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of "Buy" and an average target price of $30.00.

Astria Therapeutics Trading Up 3.9 %

ATXS opened at $5.36 on Monday. Astria Therapeutics, Inc. has a 1-year low of $3.56 and a 1-year high of $12.92. The business has a 50 day moving average of $5.40 and a 200-day moving average of $7.85. The stock has a market capitalization of $302.49 million, a price-to-earnings ratio of -2.56 and a beta of 0.45.

Astria Therapeutics (NASDAQ:ATXS - Get Free Report) last released its earnings results on Tuesday, March 11th. The biotechnology company reported ($0.44) earnings per share for the quarter, topping analysts' consensus estimates of ($0.45) by $0.01. Equities analysts predict that Astria Therapeutics, Inc. will post -1.65 EPS for the current year.

Astria Therapeutics Company Profile

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.